Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | GABRE | P78334 | 1/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21722371 | 0.81 | LOXL2 (0.36) | NOS3NOS1NOS2AGBL2 | |
| SCHEMBL2121398 | 0.79 | MAP4K4 (0.34) | AGBL2USP7 | |
| SCHEMBL2123145 | 0.79 | LMNA (0.47) | NOS3NOS1NOS2DHFR | |
| SCHEMBL2422235 | 0.78 | NOS3 (0.45) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL21914765 | 0.78 | AGBL2 (0.39) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL31248042 | 0.77 | MAPK1 (0.41) | AGBL2 | |
| SCHEMBL25467228 | 0.77 | DHFR (0.45) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL31587245 | 0.77 | NOS3 (0.56) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL12647715 | 0.77 | NOS3 (0.56) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL22842950 | 0.77 | AGBL2 (0.46) | NOS3NOS1NOS2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133271-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NodThera Limited (GB) | 2023-07-13 | — | — | WO | disclosed |
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| CN-101796053-A | Piperidine derivatives useful as orexin receptor antagonists | GLAXO GROUP LTD | 2010-08-04 | — | — | CN | disclosed |
| EP-2176258-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| WO-2009003993-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003993-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, GPR119 | NOS3 1521/4885NOS1 1176/4885NOS2 1266/4885 |
| US-20090022670-A1 | NOVEL COMPOUNDS | UGT1A1, UGT2B7, ABCB1 | NOS3 3658/4885NOS1 3680/4885NOS2 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.